[Use of cyanoacrylate in the endoscopic therapy of gastric varices: experience in the National Hospital Edgardo Rebagliati Martins from 2006 to 2010]

Rev Gastroenterol Peru. 2011 Jul-Sep;31(3):208-15.
[Article in Spanish]

Abstract

Objective: To evaluate the therapeutic success of the injection of N-butyl-2 cyanoacrylate in the treatment of gastric varices.

Methods: Cross-sectional study included 33 patients with gastric varices who only received cyanoacrylate endoscopic therapy between 2006 and 2010. Intravariceally, cyanoacrylate was injected in a 1:1 dilution with lipiodol until the obliteration of varices. The therapeutic situation was: active bleeding, varices with stigmata of recent bleeding and secondary prophylaxis. Treatment success was evaluated according to hemostasis, recurrent bleeding and obliteration.

Results: Of the 33 patients, 3 (9.1%) were for active bleeding, 20 (60.6%) with stigmata of recent bleeding and 10 (30.3%) as secondary prophylaxis. Gastric varices were GOV2, 17 (51.5%); IGV1, 14 (42.4%); GOV1, 2 (6.1%). Hemostasis was achieved in 21 (91.3%) and in 2 (66.7%) of 3 patients with active bleeding. Five (15.6%) patients had recurrent bleeding and 2 of them used cyanoacrylate with successful hemostasis. Obliteration was achieved. Four patients died and one for failure of control bleeding. A high severity of Child-Pugh classification was related to treatment endoscopic failure (p=0.034). The main complication was bleeding after the injection of cyanoacrylate.

Conclusions: Our results support the use of cyanoacrylate in the treatment of gastric varices with few major complications.

Publication types

  • Evaluation Study

MeSH terms

  • Aged
  • Cross-Sectional Studies
  • Enbucrilate / therapeutic use*
  • Esophageal and Gastric Varices / therapy*
  • Female
  • Gastrointestinal Hemorrhage / therapy*
  • Gastroscopy*
  • Hemostasis, Endoscopic*
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Sclerosing Solutions / therapeutic use*
  • Sclerotherapy*
  • Treatment Outcome

Substances

  • Sclerosing Solutions
  • Enbucrilate